Multifactorial Pathogenesis, Diagnosis, and Therapeutic Strategies in Alzheimer’s Disease
DOI:
https://doi.org/10.61173/42726n83Keywords:
Alzheimer’s disease, Multifactorial pathogenesis, Amyloid protein, Tau, Neuroinflammation, Biomarkers, Disease-modifying therapyAbstract
Alzheimer's disease (AD) has traditionally been explained by the amyloid cascade hypothesis as its core mechanism. However, the limitations of single-target therapies reflect that AD cannot be simply explained by a linear pathogenic mechanism. This review examines key mechanisms including the Aβ-tau axis, neuroinflammation, genetic factors, and mitochondrial metabolic abnormalities, proposing that AD pathogenesis should instead be modeled as a multifactorial pathological network. Different pathological nodes amplify disease severity collectively, with multiple factors synergistically driving neuronal network dysfunction and cognitive decline. The review also examines trends in blood biomarkers, imaging, and digital metrics, exploring stratified diagnostics and nodetargeted therapies for multifactorial pathogenesis. This model integrates diverse mechanisms into a comprehensive disease network, providing a theoretical foundation for precision medicine.
References
pathogenic factor remains insufficient for effective disease 2. World Health Organization. Dementia. 2025. Available from: treatment [50]. Alternatively, stem cell and gene therapies https://www.who.int/zh/news-room/fact-sheets/detail/dementia hold promising research potential. Animal studies indicate 3 . H e n e k a M T, E l K h o u r y J , Wy s s - C o r a y T, e t a l . neural stem cells may improve synaptic function and in- Neuroinflammation in Alzheimer’s disease. Lancet Neurol. flammatory states through paracrine mechanisms [44–47]. 2015;14(4):388–405. The advent of gene delivery technologies provides feasi- 4. Frisoni GB, Hansson O, Nichols E, et al. New landscape of ble approaches for gene therapy [48,49]. Future AD treat- the diagnosis of Alzheimer’s disease. Lancet. 2025;406:1389– ments are more likely to focus on disease modification, 1407. utilizing biomarkers to assess therapeutic efficacy. Simul- 5. Howard R, McShane R, Lindsay J, et al. Donepezil and taneously targeting multiple pathogenic factors resembles memantine for moderate-to-severe Alzheimer’s disease. N Engl the "cocktail therapy" approach used in HIV treatment J Med. 2012;366:893–903. [42,43]. 6. Kepp KP, Robakis NK, Høilund-Carlsen PF, et al. The amyloid cascade hypothesis: an updated critical review. Brain. 2023;146(10):3969–3990. 5. Conclusions and Outlook 7. Povala G, Bellaver B, Bastiani MAD, Ferrari-Souza JP, et Based on accumulating evidence in recent years, the al. Amyloid beta and tau are associated with the dual effect of pathogenesis of Alzheimer’s disease (AD) is better neuroinflammation on neurodegeneration. Alzheimers Dement. conceptualized as a multifactorial, multilevel dynamic 2025 Oct;21(10):e70746. framework rather than a linear process driven by a single 8. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. pathogenic factor [6,38,41]. Key contributors, including Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl neuroinflammation, synaptic dysfunction, mitochondri- Acad Sci USA. 2002;99:6364–6369. al metabolic imbalance, and genetic susceptibility, are 9. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing highly interconnected and mutually regulated, collec- endogenous tau ameliorates amyloid beta-induced deficits in an tively shaping disease progression across different stages Alzheimer's disease mouse model. Science. 2007;316:750–754. [3,16,18,20,21]. 10. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction A single hypothesis is no longer sufficient to explain the prevents Abeta-induced defects in axonal transport. Science. marked heterogeneity observed in AD in terms of clin- 2010;330:198–202. ical manifestations, pathological burden, and treatment 11. Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is responses [1,19,43]. Increasing evidence from the limited required for amyloid {beta}-induced impairment of hippocampal efficacy of Aβ-targeting therapies, along with advances long-term potentiation. J Neurosci. 2011;31:1688–1692. in understanding immune and metabolic dysregulation, 12. Roberson ED, Halabisky B, Yoo JW, et al. Amyloid-β/Fynsuggests that AD more closely reflects a state of systemic induced synaptic, network, and cognitive impairments depend neuronal network dysfunction [35-39,3,16]. This multi- on tau levels in multiple mouse models of Alzheimer's disease. J factorial framework also provides important implications Neurosci. 2011;31(2):700–711. for diagnosis and treatment. Emerging approaches, such 13. Han J, Zhang Z, Zhang P, et al. The roles of microglia and as blood-based biomarkers, enable clinicians to assess astrocytes in neuroinflammation of Alzheimer’s disease. Front Aβ deposition and tau pathology more precisely [22- Neurosci. 2025;19:1575453. 27], while therapeutic strategies should align with dis- 14. Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing ease stage and dominant pathological drivers, favoring sustains the microglial response in an Alzheimer’s disease multi-target interventions over single-target approaches model. Cell. 2015;160:1061–1071. [40,42,43]. 15. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose Looking forward, a central objective of future AD re- of apolipoprotein E type 4 allele and the risk of Alzheimer's search is to further refine this multifactorial framework by disease in late onset families. Science. 1993;261:921–923. integrating diverse lines of evidence and clarifying the in- 16. D’Alessandro MCB, Kanaan S, Geller M, et al. teractions and synergistic effects among key pathological Mitochondrial dysfunction in Alzheimer’s disease. Ageing Res processes [27,41]. Such efforts will help establish a more Rev. 2025;107:102713. Dean&Francis ISSN 2959-409X 17. Lanoiselée HM, Nicolas G, Wallon D, et al. APP, PSEN1, 34. Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation and PSEN2 mutations in early-onset Alzheimer disease. PLoS of smartphone-based testing to generate exploratory outcome Med. 2017;14:e1002270. measures in a phase 1 Parkinson's disease clinical trial. Mov 18. Swerdlow RH. Mitochondria and mitochondrial cascades in Disord. 2018;33:1287–1297. Alzheimer’s disease. J Alzheimers Dis. 2018;62:1403–1416. 35. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in 19. 2024 Alzheimer’s disease facts and figures. Alzheimers early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. Dement. 2024;20:700–789. 36. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in 20. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, early Alzheimer’s disease. N Engl J Med. 2021;384:1691–1704. sex, and ethnicity on the association between apolipoprotein 37. Knopman DS, Jones DT, Greicius MD. Failure to E genotype and Alzheimer disease. A meta-analysis. APOE demonstrate efficacy of aducanumab: An analysis of the and Alzheimer Disease Meta Analysis Consortium. JAMA. EMERGE and ENGAGE trials as reported by Biogen, December 1997;278:1349–1356. 2019. 2021;17:696–701. 21. Rajabli F, Feliciano BE, Celis K, et al. Ancestral origin of 38. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's ApoE ε4 Alzheimer disease risk in Puerto Rican and African disease at 25 years. EMBO Mol Med. 2016;8:595–608. American populations. 2018;75:547–553. 39. Rabinovici GD. Amyloid-Targeting Monoclonal Antibodies 22. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative for Alzheimer Disease. JAMA. 2023 Aug 8;330(6):507-509. accuracy of plasma phospho-tau217 for Alzheimer disease vs 40. Cummings J, Lee G, Nahedian Z, et al. Alzheimer’s disease
other neurodegenerative disorders. JAMA. 2020;324(8):772– drug development pipeline: 2023. Alzheimer’s Dement (N Y). 781. 2023;9:e12385. 23. Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: 41. Hampel H, Hardy J, Blennow K, et al. The amyloid-β a new biomarker for incipient Alzheimer's disease pathology. pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26:5481– Acta Neuropathol. 2021;141:709-724. 5503. 24. Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood 42. Cummings J, Fox N. Defining disease modifying therapy for Biomarkers to Detect Alzheimer Disease in Primary Care and Alzheimer’s disease. J Prev Alzheimers Dis. 2017;4(2):109-115. Secondary Care. JAMA. 2024;332:1245–1257. 43. Knopman DS, Amieva H, Petersen RC, et al. Alzheimer 25. U.S. Food and Drug Administration. FDA clears first blood disease. Nat Rev Dis Primers. 2021;7:33.
test used in diagnosing Alzheimer’s disease. 2024. 44. Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. 26. Mintzker Y. Blood biomarkers to detect Alzheimer disease. Neural stem cells improve cognition via BDNF in a transgenic JAMA. 2025;333:634. model of Alzheimer disease. Proc Natl Acad Sci USA. 27. Hansson O, Blennow K, Zetterberg H, Dage J. Blood 2009;106:13594–13599. biomarkers for Alzheimer’s disease in clinical practice and trials. 45. Duncan T, Valenzuela M. Alzheimer's disease, dementia, and Nat Aging. 2023;3:506–519. stem cell therapy. Stem Cell Res Ther. 2017;8:111. 28. Chan VTT, Sun ZH, Tang SM, et al. Spectral-Domain OCT 46. Kim HJ, Seo SW, Chang JW, et al. Stereotactic brain Measurements in Alzheimer's Disease: A Systematic Review and injection of human umbilical cord blood mesenchymal stem cells Meta-analysis. Ophthalmology. 2019;126:497–510. in patients with Alzheimer's disease dementia: A phase 1 clinical 29. Yoon SP, Grewal DS, Thompson AC, et al. Retinal trial. Alzheimers Dement (N Y). 2015 Jul 26;1(2):95-102. Microvascular and Neurodegenerative Changes in Alzheimer's 47. Losurdo M, Pedrazzoli M, D’Agostino C, et al. Intranasal Disease and Mild Cognitive Impairment Compared with Control delivery of mesenchymal stem cell-derived extracellular vesicles Participants. Ophthalmol Retina. 2019;3:489–499. exerts immunomodulatory and neuroprotective effects in a 3xTg 30. Cheung CY, Ikram MK, Chen C, Wong TY. Imaging retina model of Alzheimer's disease. Stem Cells Transl Med. 2020 to study dementia and stroke. Prog Retin Eye Res. 2017;57:89– Sep;9(9):1068-1084. 107. 48. Hudry E, Vandenberghe LH. Therapeutic AAV Gene 31. Wen J, Thibeau-Sutre E, Diaz-Melo M, et al. Convolutional Transfer to the Nervous System: A Clinical Reality. Neuron. neural networks for classification of Alzheimer's disease: 2019;101:839–862. Overview and reproducible evaluation. Med Image Anal. 2020 49. Lee CYD, Daggett A, Gu X, et al. Elevated TREM2 Gene Jul:63:101694. Dosage Reprograms Microglia Responsivity and Ameliorates 32. Suk HI, Lee SW, Shen D.Hierarchical feature representation Pathological Phenotypes in Alzheimer's Disease Models. and multimodal fusion with deep learning for AD/MCI Neuron. 2018 Mar 7;97(5):1032-1048.e5. diagnosis. NeuroImage. 2014;101:569–582. 50. Hocquemiller M, Giersch L, Audrain M, et al. Adeno- 33. Dodge HH, Zhu J, Mattek NC, et al. Web-enabled Associated Virus-Based Gene Therapy for CNS Diseases. Hum Conversational Interactions as a Means to Improve Cognitive Gene Ther. 2016;27:478–496. Functions: Results of a 6-Week Randomized Controlled Trial. Alzheimer’s Dement (N Y). 2015;1:1–12.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
